Ftse Mib
34.228,77
0,71%
DAX
18.430,05
1,42%
S&P 500
5.192,76
0,23%
NASDAQ
16.387,27
0,23%
Bitcoin
63.597,96
0,68%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BriaCell Therapeutics Corporation (BCTX) BriaCell Therapeutics Corporation (BCTX) Notizie

BriaCell Therapeutics Corporation

BCTX
2,24
-0,03 (-1,32%)
Ultimo aggiornamento: 18:40:25
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202414:00GLOBEBriaCell Announces Oral and Poster Presentations at ASCO..
10/4/202414:00GLOBEBriaCell 2024 AACR Preclinical Poster Confirms Strong..
09/4/202414:00GLOBEBriaCell Showcases Data Demonstrating Unmatched..
07/3/202414:00GLOBEBriaCell Receives and Executes Letter of Intent to Advance..
06/3/202414:00GLOBEBriaCell to Present Clinical Data in Central Nervous System..
27/2/202414:00GLOBEBriaCell Provides Update on Alleged Illegal Trading of..
07/2/202414:00GLOBEBriaCell Announces Strong Clinical Data in Breast Cancer..
06/2/202414:30GLOBEBreaking Ground in Prostate Cancer: BriaCell Announces Lead..
01/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
31/1/202423:24EDGAR2Form 8-K - Current report
31/1/202404:48GLOBEBriaCell Therapeutics Corp. Announces Results of Shareholder..
22/1/202423:00EDGAR2Form S-3 - Registration statement under Securities Act of..
09/1/202422:05EDGAR2Form DEF 14A - Other definitive proxy statements
04/1/202414:45GLOBEBriaCell Images Confirm Robust Anti-Tumor Activity in..
28/12/202314:55GLOBEBriaCell Reports 71% Central Nervous System Response Rate in..
20/12/202322:05EDGAR2Form 8-K - Current report
20/12/202314:40GLOBEBriaCell Reports Unprecedented Preliminary Survival and..
14/12/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/12/202323:00EDGAR2Form 8-K - Current report
06/12/202315:31GLOBEBriaCell Highlights Outstanding Topline Survival and..
06/12/202315:00GLOBEBriaCell 2023 SABCS Posters Confirm Activation of..
30/11/202313:00EDGAR2Form 8-K - Current report
30/11/202313:00GLOBEBriaCell Records New Responder with Remarkable Improvement..
03/11/202313:31GLOBEBriaCell Reports Unprecedented Anti-Tumor Activity of its..
25/10/202315:15GLOBEBriaCell Forms Medical Advisory Board of Distinguished..
20/10/202315:15GLOBEOctober is Breast Cancer Awareness Month – BriaCell is..
18/10/202315:00GLOBEBriaCell Announces Presentations at the 2023 Society for the..
11/10/202315:10GLOBEBriaCell To Host Virtual Key Opinion Leader Event on..
04/10/202315:00GLOBEBriaCell Partners with New York Cancer & Blood Specialists..
03/10/202315:00GLOBEBriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in..
08/9/202313:00GLOBEBriaCell Reports Benchmark-Beating Patient Survival and..
31/8/202317:54GLOBEBriaCell Therapeutics Corp. Announces Closing of Plan of..
31/8/202314:21GLOBEBriaCell Accepts Letter of Intent from Weill Cornell..
25/8/202320:33GLOBEBriaCell Receives Court Approval for the Share Arrangement..
18/8/202318:21GLOBEBriaCell Therapeutics Corp. Announces Voting Results From..
16/8/202314:36GLOBEBriaCell Awarded National Cancer Institute Grant to Advance..
27/6/202315:37APSNews Brief: BriaCell Therapeutics Corp.
27/6/202314:05GLOBEFDA Approves BriaCell’s Pivotal Registrational Study Design..
25/5/202315:00GLOBEBriaCell Enters Definitive Arrangement Agreement for the..
19/5/202317:38GLOBEBriaCell Closes $4 Million Strategic Investment by Prevail..
15/5/202314:00GLOBEBriaCell Announces $4 Million Strategic Investment and..
Apertura: 2,24 Min: 2,20 Max: 2,28
Chiusura: 2,27

La tua Cronologia

NASDAQ
BCTX
BriaCell Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network